ArriVent BioPharma, Inc. - 8-K Filing
ArriVent BioPharma filed to update its at-the-market offering program by authorizing up to $250 million in common stock sales through Jefferies LLC under a Sales Agreement dated February 3, 2025. The Prospectus Supplement was filed on May 11, 2026, as part of the company's existing shelf registration statement (File No. 333-284661). (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $AVBP